Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 27, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, alleging that the company concealed significant cost overruns and execution problems on key infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver among its three segments [2]. Allegations and Issues - The lawsuit claims that FLR concealed substantial cost overruns and execution issues on major projects, including the Gordie Howe International Bridge and I-635/LBJ, which were affected by subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategies while failing to disclose the full impact of reduced client spending and macroeconomic uncertainties [3]. Financial Performance - Despite the ongoing issues, FLR reaffirmed its financial guidance in May 2025. However, on August 1, 2025, the company reported second-quarter results that significantly missed expectations, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disappointing results, FLR cut its full-year guidance, leading to a 27.04% drop in stock price to $41.42 on August 1, 2025, prompting analysts to downgrade the stock due to lost confidence in management's disclosures and project oversight [4].

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612, and pending in the Southern District of New York – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's top executives with violations of the Securities Exchange Act of 1934. http ...

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Netflix, Inc. and its executives regarding misleading statements about the company's business and operations [1][2]. Company Overview - Netflix provides entertainment services with over 300 million paid memberships across more than 190 countries [2]. Investigation Details - The investigation focuses on whether Netflix and certain top executives made materially false and/or misleading statements or omitted material information related to Netflix's business and operations [2]. Law Firm Background - Robbins Geller is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone, which is more than the next five law firms combined [3]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors [3]. - Robbins Geller has a history of obtaining significant securities class action recoveries, including the largest ever at $7.2 billion in the Enron case [3].

This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. The co-founder and CFO of a Miami investment firm that once bought stakes in prominent sports teams around the world are now facing federal charges. According to an Oct. 16 announcement from the FBI, 777 Partners Co-Founder Joshua Wander has been charged with conspiracy to commit wire fraud, wire fraud, conspiracy to commit securities fraud and securities fraud. FBI officia ...

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding the company's financial health and ability to manage macroeconomic challenges during the specified class period from January 30, 2025, to July 23, 2025 [1][4]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [4]. - It is alleged that the true impact of competitive pressures, declining global sales, and product oversupply on Dow's business was understated [4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which led to a stock price drop of over 3% [5]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [6]. - Following the disappointing Q2 results, Dow's stock price fell by more than 17%, and the company announced a dividend cut from $0.70 to $0.35 per share [6]. Group 2: Legal Process and Representation - Investors who purchased Dow securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [7]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [7]. Group 3: About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8]. - The firm has been recognized for obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [9].

Core Points - A securities class action lawsuit has been filed against Fortinet, Inc. for alleged misleading statements and omissions during the Class Period from November 8, 2024, to August 6, 2025 [1][2] - The lead plaintiff deadline for investors to seek representation is November 21, 2025 [1][3] Allegations Against Fortinet - The complaint claims that Fortinet misrepresented the profitability of its refresh cycle, stating it would be more lucrative than it actually was, as it involved old products that constituted a "small percentage" of the business [2] - Fortinet allegedly concealed the true number of FortiGate firewalls eligible for upgrades, leading to misleading statements about the company's operations and prospects [2] - The company is accused of misrepresenting the momentum of the refresh cycle, having pushed through approximately half of it in just a few months by the end of Q2 2025, contrary to claims of gradual growth over two years [2]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences over traditional monoclonal antibody treatments [4]. Allegations and Discrepancies - The lawsuit alleges that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, has faced serious malfunctions, including under-infusion and over-infusion, which jeopardized patient safety [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the rollout in Canada would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Tronox Holdings plc common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the Class Period from February 12, 2025, to July 30, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Tronox common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 3, 2025 [3]. - The lawsuit alleges that Tronox made positive statements about its growth and revenue projections while concealing adverse facts about its commercial division's performance [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].